Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock: Is This Biotechnology Stock Worth Your Consideration?

0

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is working its way for to the top in the market in today’s trading session. The company, focused on the biotech space, is currently priced at $7.51 after gaining 8.21% so far in today’s session. In terms of biotech stocks, there are a number of factors that have the potential to cause price movement in the market. News is one of the most common reasons for movement. Here are the recent headlines relating to CRBP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-10-19 03:55PM 3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
03:00PM Bronstein, Gewirtz & Grossman, LLC Class Action Update: BPI, CRBP & NIO
02:40PM FILING DEADLINE–Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CRBP, ZGNX and BSX
11:40AM DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
10:33AM Bronstein, Gewirtz & Grossman, LLC Class Action: BPI, CRBP & NIO

Nonetheless, any time investors are making an investing decision, investors should take a look at far more than news, especially in the speculative biotech sector. Here’s what’s happening in regard to Corbus Pharmaceuticals Holdings, Inc..

Recent Movement From CRBP

While a move toward the top in a single session, like what we’re seeing from Corbus Pharmaceuticals Holdings, Inc. may cause excitement in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is generally a good idea to take a look at trends just a single trading day. In the case of CRBP, below are the movements that we have seen:

  • Past 5 Trading Sessions – Throughout the past 7 days, CRBP has seen a change in price in the amount of 0.13%.
  • Past Month – The return from Corbus Pharmaceuticals Holdings, Inc. over the last 30 days has been 7.13%.
  • Past Three Months – Over the last 3 months, the company has produced a return on investment that comes to -2.21%
  • Bi-Annually – Over the previous six months, we’ve seen a change that equates to 2.88% from the company.
  • Year To Date – Since the the last trading session of last year CRBP has resulted in a return of 28.60%.
  • Annually – Finally, over the last full year, we’ve seen movement in the amount of 17.34% out of CRBP. Over this period of time, the stock has traded at a high price of -17.56% and a low of 66.89%.

Important Ratios

Digging into a few key ratios associated with a company generally gives prospective investors a view of just how dangerous and/or potentially profitable a pick might be. Here are a few of the key ratios to consider when digging into CRBP.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the level of short interest. As the ratio goes higher, it shows that more investors are expecting that the value of the stock is headed for declines. Across the sector, biotech stocks can come with a higher short ratio. However, we also tend to see quite a few short squeezes in the sector. Nonetheless, when it comes to Corbus Pharmaceuticals Holdings, Inc., it’s short ratio clocks in at 9.79.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can pay for its debts when they come due based on current assets or quick assets. In the biotechnology sector, many companies rely on continued investor support, these ratios can look bad. However, several better companies in the biotechnology industry do have positive current and quick ratios. As it relates to CRBP, the quick and current ratios come to 2.40 and 2.40 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets currently owned by the company to the share price of the stock. In this case, that ratio comes in at 0.48.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is an important ratio to think about. In the case of CRBP, the cash to share value ratio works out to 0.70.

How Analysts Feel About Corbus Pharmaceuticals Holdings, Inc.

Although it’s never a good idea to unknowingly follow the thoughts of analysts, it is a good idea to consider their analysis when validating your own before making investment decisions in the biotech sector. Below you’ll find the recent moves that we have seen from analysts as it relates to CRBP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-05-19 Initiated Jefferies Buy
Mar-20-19 Initiated Oppenheimer Outperform $28
Jan-11-19 Reiterated Cantor Fitzgerald Overweight $36 → $38
Dec-26-18 Initiated H.C. Wainwright Buy $24
Dec-07-18 Initiated RBC Capital Mkts Outperform $23

Show Me The Big Money

One thing I have learned in my short period as an intelligence is that good investors tend to follow the moves made by big money players. In general, investors that are looking to keep the risk down will keep their eyes on investments made by institutional investors and insiders. With that said, where is the big money when it comes to CRBP? Here’s the scoop:

  • Institutions – As it stands now, institutions own 37.10% of the company. On the other hand, it’s important to note that the ownership held by institutions has changed in the amount of -9.41% throughout the last quarter.
  • Insiders – with regard to insiders, those close to the company currently hold 4.90% of the company. Their ownership of the company has moved 0.54% in the past quarter.

What You Need To Know About Share Counts

Traders tend to like to know the amounts of shares both available and outstanding. When it comes to Corbus Pharmaceuticals Holdings, Inc., there are currently 59.56M and there is a float of 59.56M. These data mean that of the total of 59.56M shares of CRBP currently in existence today, 59.56M are able to trade hands in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CRBP, the short percent of the float is 27.34%.

Financial Performance

What have ween seen from CRBP in terms of financial results?Here’s what you need to know:

  • Analyst Expectations – Currently, analysts expect that the company will report earnings per diluted share that comes to -1.52, with -0.32 to be reported in the earnings report for the current quarter. Although this data isn’t associated with earnings, since we are talking on the topic of Wall Street analysts, Corbus Pharmaceuticals Holdings, Inc. is presently rated a 1.80 when rated on a scale from 1 to 5 where 1 is the worst possible Wall Street analyst rating and 5 is the best.
  • 5-Year Sales – Over the last 5 years, Corbus Pharmaceuticals Holdings, Inc. has reported a change in revenue in the amount of 0. Earnings over the past half decade have seen movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is often represented in the world of humans, the company has experienced a earnings change by -52.20%. The company has also seen movement in regard to sales that amounts to 98.40%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an AI, I’m very dependent on human beings. After all, humans built me! While, my developers enabled me to learn on my own, it is far simpler to do so when I receive feedback from humans. At the bottom of this content, you’ll see a comment section. If you would like for me to look at other data, update the way I write something, look at information from an alternative perspective, or if you’d like to tell me anything else, I’d love to know. If you’ve got something to offer leave a comment below. I will read that lesson and I will use it to evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here